Document:

Third Amended and Restated Right of First Refusal and Co-Sale Agreement

 Exhibit 4.3 
 WHITEGLOVE HOUSE CALL HEALTH, INC. 
 THIRD AMENDED AND RESTATED RIGHT OF
FIRST REFUSAL AND CO-SALE 
 AGREEMENT 
 THIS THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (the “Agreement”) is made as of March 2, 2011 by and among Whiteglove House Call Health,
Inc., a Texas corporation (the “Company”), the persons listed on Schedule I hereto (each, an “Investor” and collectively, the “Investors”) and the
persons listed on Schedule II hereto (each, a “Common Shareholder” and collectively, the “Common Shareholders”). The Investors and Common Shareholders are sometimes referred
to herein individually as a “Shareholder” and collectively as the “Shareholders.” 
 RECITALS: 
 WHEREAS, the Company and certain of the
Investors are parties to the Series D Preferred Stock Purchase Agreement dated as of even date herewith (the “Purchase Agreement”) by and among the Company and the Investors listed on Schedule I thereto, pursuant to which
such Investors are purchasing shares of the Company’s Series D Convertible Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”, and together with the Company’s Series A
Convertible Preferred Stock, par value $0.01 per share (the “Series A Convertible Preferred Stock”), Series A-l Convertible Preferred Stock, par value $0.01 per share (the “Series A-1 Convertible Preferred
Stock”, and collectively with the Series A Convertible Preferred Stock, the “Series A Preferred Stock”), Series B-l Convertible Preferred Stock, par value $0.01 per share (the “Series B-1
Preferred Stock”), and Series C Convertible Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”), the “Preferred Stock”); 

WHEREAS, the parties hereto desire to restrict the sale, assignment, transfer, encumbrance or other disposition of securities of
the Company (collectively, the “Securities”) that the Shareholders currently own or may hereafter acquire, and to provide for certain rights and obligations in respect thereto as hereinafter provided; and 

WHEREAS, the execution and delivery of this Agreement by the Company, the Investors and Common
Shareholders is a condition to the closing of the issuance, sale and purchase of the Series D Preferred Stock pursuant to the Purchase Agreement. 
 AGREEMENT: 
 NOW, THEREFORE, in consideration of the
foregoing premises, and the mutual promises and agreements contained herein, the parties hereto hereby agree as follows: 
 1.
Transfer Restrictions. 
 (a) Restriction on Transfer.
During the term of this Agreement, all of the Securities now owned or hereafter acquired by each Shareholder shall be subject to the terms and conditions of this Agreement. No transfer, whether voluntary or involuntary, of the Securities shall
be valid unless it is made pursuant to the terms and conditions of this Agreement. 

  
 1 

 (b) Unvested Shares. Notwithstanding anything to
the contrary contained herein, a Shareholder shall not be permitted to transfer any Securities until such time as (i) the vesting restrictions with respect to such Securities have lapsed and (ii) the Company’s and the Investors’
right of repurchase with respect to such Securities has terminated. 
 (c) Permitted
Transactions. Notwithstanding the foregoing, the rights of first refusal of the Company and the Investors, as set forth below in Section 2, and the co-sale right of the Investors, as set forth below in
Section 3, shall not apply to (i) repurchases of Securities of a Common Shareholder pursuant to any restricted stock purchase agreement or similar agreement between the Common Shareholder and the Company that provides the Company
with the right to repurchase such Securities; (ii) any transfer of Securities by a Shareholder to any such Shareholder’s spouse, parents, siblings (by blood, marriage or adoption) or lineal descendants (by blood, marriage or adoption)
(collectively, “Immediate Family”); (iii) any transfer of Securities by a Shareholder that is a partnership to any such Shareholder’s partners or retired partners (collectively, “Partners”);
(iv) any transfer of Securities by a Shareholder that is a limited liability company to any such Shareholder’s members (collectively, “Members”); (v) any transfer of Securities by a Shareholder to a trust,
partnership, corporation, limited liability company or other similar entity owned exclusively by such Shareholder and/or such Shareholder’s Immediate Family, Partners or Members for the benefit of such Shareholder or such Shareholder’s
Immediate Family, Partners or Members; (vi) any transfer of Securities by a Shareholder, or upon a Shareholder’s death to the executors, administrators, testamentary trustees, legatees or beneficiaries of such Shareholder; (vii) any
transfer of Securities by a Shareholder to any person who controls, is controlled by or is under common control (within the meaning of the Securities Act of 1933, as amended (the “Securities Act”)) with such Shareholder; or
(viii) any transfer of Securities by a Shareholder pursuant to a bona fide loan transaction which creates a mere security interest in the Securities; (ix) any redemption of the Series C Preferred Stock or Series D Preferred Stock Pursuant
to Article IV, Section (B)(3) of the Seventh Amended and Restated Certificate of Formation of the Company (the “Restated Certificate”); provided, however, that in each of clauses (ii) through (ix), each
transferee, donee, heir or distributee shall, as a condition precedent to such transfer, become a party to this Agreement by executing an Adoption Agreement substantially in the form attached as Exhibit A and shall have all of the
rights and obligations of a Shareholder hereunder, and all interests in any trust, partnership, corporation, limited liability company or other similar entity to which any Securities are transferred shall themselves be deemed Securities and shall be
subject to all of the provisions hereof. Such transferred Securities shall remain “Securities” hereunder, and such transferee shall be treated as a “Shareholder”
for the purposes of this Agreement. 
 (d) Company Repurchase or Public Offering.
The provisions of this Agreement shall not apply to the sale of any Securities (i) to the public pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission under the Securities Act or
(ii) to the Company other than pursuant to the operation of Section 2 below. 

  
 2

 2. Right of First Refusal. 

(a) Grant. Subject to the terms hereof, the Company and, to the extent such right is waived by
the Company, the Investors are each hereby granted a right of first refusal with respect to any proposed disposition of any Securities held by the Shareholders (except for a permitted transferee of the Stock under Section l(c) hereof), in the
following order of priority: 
 (i) The Company shall have the first right to purchase any Securities proposed to
be transferred to a third-party by a Shareholder; and 
 (ii) In the event the Company elects not to exercise its
first refusal rights with respect to all or any portion of such proposed transfer, the Company agrees to waive such rights with respect to such portion in favor of the Investors’ right of first refusal and co-sale right under this Agreement.

 (b) Notice of Intended Disposition. In the event a Shareholder desires to sell or
otherwise transfer any or all of the Securities held by such Shareholder other than a permitted transfer pursuant to Section l(c) (in such capacity such Shareholder shall hereafter be called a “Selling
Shareholder” and the shares proposed to be sold or transferred to be hereafter called the “Target Shares”), the Selling Shareholder shall promptly deliver to the Company and the Investors written notice of
the intended disposition (“Disposition Notice”). Each Disposition Notice shall certify that the Selling Shareholder has received a firm offer from the prospective unaffiliated third party and shall contain all material terms
of the proposed transfer, including, without limitation, a copy of the written offer received, the name and address of the prospective purchaser (or transferee), the purchase price and terms of payment, the date and place of the proposed transfer,
and the number and description of Securities proposed to be transferred by the Selling Shareholder. 
 (c)
Exercise of Right by Company. The Company shall, for a period of fifteen (15) days following receipt of the Disposition Notice, have the right to repurchase all or any portion of the Target Shares upon the same terms
and conditions specified in the Disposition Notice, subject to the following conditions. Such right shall be exercisable by written notice (the “Exercise Notice”) delivered to the Selling Shareholder and the Investors prior
to the expiration of the fifteen (15) day exercise period. If such right is exercised with respect to all the Target Shares specified in the Disposition Notice, then the Company shall effect the repurchase of such Target Shares, including
payment of the purchase price, no later than the later of (i) thirty (30) days after the date of the Disposition Notice is given or (ii) the date contemplated in the Disposition Notice for the closing with the prospective third party
transferee(s). At such time, the Selling Shareholder shall deliver to the Company the certificates representing the Target Shares to be repurchased, each certificate to be properly endorsed for transfer. Alternatively, if such right is exercised
with respect to only a portion of the Target Shares specified in the Disposition Notice, the Company shall notify the Investors of its intent to repurchase only a portion of the Target Shares within the fifteen (15) day exercise period above
defined. The Company’s repurchase of such Target Shares shall be consummated at the time of the Investors’ exercise of its purchase rights in accordance with Section 2(e) herein. In the event the Investors do not elect to
purchase any of the remaining Target Shares, the Company’s repurchase of that portion of the Target Shares that the Company desires to repurchase shall be consummated not more than thirty (30) days after the date of expiration of the
Investors’ first refusal right. 

  
 3

 Should the purchase price specified in the Disposition Notice be payable in
property other than cash or evidences of indebtedness, the Company shall have the right to pay the purchase price in the form of cash equal in amount to the value of such property or evidence of indebtedness. If the Selling Shareholder and the
Company cannot agree on such cash value within ten (10) days after the Company’s receipt of the Disposition Notice, the valuation shall be made by an appraiser of recognized standing mutually selected by the Selling Shareholder and the
Company or, if they cannot agree on an appraiser within twenty (20) days after the Company’s receipt of the Disposition Notice, each shall select an appraiser of recognized standing and the two appraisers shall designate a third appraiser
of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by the Selling Shareholder and the Company. The closing shall then be held on the later of (i) thirty
(30) days following the delivery of the Exercise Notice or (ii) thirty (30) days after such valuation shall have been determined. 
 (d) Deemed Non-Exercise of Right. In the event the Exercise Notice is not given by the Company to the Selling Shareholder and the Investors within fifteen (15) days
following the date of the Company’s receipt of the Disposition Notice, the Company shall be deemed to have waived its right of first refusal with respect to such proposed disposition. 

(e) Exercise of Right by the Investors. Subject to the rights of the Company, the Investors
shall, for a period ending on the earlier of (i) thirty (30) days from receipt of the Disposition Notice or (ii) fifteen (15) days from receipt of written notice of the Company’s election either to waive its right of first
refusal or to repurchase only a portion of the Target Shares, have the right to purchase up to that number of Target Shares equal to the product of (A) the number of remaining Target Shares multiplied by (B) a fraction, the numerator of
which shall be the number of shares of Common Stock owned by such Investor (assuming full conversion and exercise of all convertible and exercisable securities into Common Stock held by such Investor) and the denominator of which shall be the number
of shares of Common Stock owned by all of the Investors (assuming full conversion and exercise of all convertible and exercisable securities into Common Stock) (the “Proportionate Share”). Each Investor shall deliver to the
Selling Shareholder a written notice stating whether it elects to exercise its option under this Section 2(e) and the maximum number of shares (up to such Investor’s Proportionate Share) that it is willing to purchase. If any
Investor does not elect to purchase its full Proportionate Share, the Proposed Seller shall promptly deliver another written notice to each other Investor that has elected to purchase its full Proportionate Share (each, a “Fully
Exercising Investor” and collectively, the “Fully Exercising Investors”) stating the number of unpurchased Target Shares. Each Fully Exercising Investor shall be entitled, by delivering written notice to
the Selling Shareholder within five (5) calendar days following delivery of such notice to such Fully Exercising Investor, to purchase up to all of the remaining Target Shares. In the event of an oversubscription for the unpurchased Target
Shares, the oversubscribed amount shall be allocated among such Fully Exercising Investors on a pro rata basis based on the number of shares of Common Stock (assuming full conversion and exercise of all convertible and exercisable securities into
Common Stock) owned by each of them. The delivery of the notice of election under this Section 2(e) shall constitute an irrevocable commitment to purchase such Target Shares, subject only to such conditions as were contained in the
Disposition Notice. The closing of the sale of Target Shares to any exercising Investors shall occur no later than the later of (i) forty-five (45) days after the Disposition Notice is given or (ii) the date contemplated in the
Disposition Notice for the closing with the prospective third party transferee(s). At such closing, the Selling Shareholder shall deliver a certificate or certificates representing the Target Shares, properly endorsed for transfer, and the
exercising Investors shall deliver payment of the purchase price therefor. 

  
 4

 (f) Non-Exercise of Right. Subject to the
Investors’ co-sale rights described in Section 3 below, in the event the Exercise Notice with respect to any portion of the Target Shares is not given to the Selling Shareholder within forty-five (45) days following the date of
the Company’s and the Investors’ receipt of the Disposition Notice, the Selling Shareholder shall have a period of thirty (30) days thereafter in which to sell the portion of the Target Shares that neither the Company nor the
Investors have elected to purchase, upon terms and conditions (including the purchase price) no more favorable to the third-party transferee than those specified in the Disposition Notice. In the event the Selling Shareholder does not notify the
Investors or consummate the sale or disposition of the Target Shares within the forty-five (45) day period, the Target Shares shall once again be subject to the right of first refusal and co-sale provided herein. Any attempt by the Selling
Shareholder to transfer Target Shares in violation of this Agreement shall be void and the Company agrees it will not effect such a transfer nor will it treat any alleged transferee(s) as a shareholder. 

3. Co-Sale Rights. 
 (a) Notice of Offer. The provisions of Section 2(b) requiring the Selling Shareholder to give notice of any intended transfer of the Securities are incorporated in this
Section 3. 
 (b) Grant of Co-Sale Rights. 

(i) If any such proposed disposition of Target Shares which is subject to Section 2 is being made by a Selling
Shareholder, all Investors (other than any Investor exercising its rights of first refusal with respect to such disposition) shall have the right, exercisable upon written notice to the Selling Shareholder within thirty (30) days after receipt
of the Disposition Notice, to participate in such sale of the Target Shares on the same terms and conditions as those set forth in the Disposition Notice. To the extent the Investors exercise such right of participation, the number of shares of
Target Shares that the Selling Shareholder may sell in the transaction shall be correspondingly reduced. The right of participation of the Investors shall be subject to the terms and conditions set forth in this Section 3. 

(ii) With regard to sales of Target Shares that are: 

(A) Common Stock, each Investor (other than any Investor exercising its rights of first refusal with respect to the
applicable disposition) may sell all or any part of a number of shares of the capital stock of the Company held by such Investor equal to the product obtained by multiplying (i) the aggregate number of Target Shares covered by the Disposition
Notice that none of the Investors have elected to purchase pursuant to Section 2 by (ii) a fraction, the numerator of which is the number of shares of Common Stock of the Company at the time owned by such Investor (assuming
conversion of all securities then outstanding that are convertible into Common Stock held by such Investor) and the denominator of which is the combined number of shares of Common Stock of the Company at the time deemed owned by the Selling
Shareholder and all of the Investors that desire to exercise their rights of co-sale (assuming the conversion of all outstanding shares of Preferred Stock). 

  
 5

 (B) Of a particular series of Preferred Stock, each Investor (other than
any Investor exercising its rights of first refusal with respect to the applicable disposition) may sell all or any part of a number of shares of such series of Preferred Stock or shares of any series of Preferred Stock senior to or pari passu
with the Target Shares based on a last in, first out basis, determined by the date on which such series of Preferred Stock was issued (e.g. shares of Series D Preferred Stock are senior to shares of Series C Preferred Stock), (collectively, the
“Permitted Preferred Co-Sale Shares”), held by such Investor equal to the product obtained by multiplying (i) the aggregate number of Target Shares comprised of such series of Preferred Stock covered by the Disposition
Notice that none of the Investors have elected to purchase pursuant to Section 2 by (ii) a fraction, the numerator of which is the number of shares of such series of Preferred Stock then outstanding and the denominator of which is
the combined number of shares of Permitted Preferred Co-Sale Shares at the time deemed owned by the Selling Shareholder and all of the Investors that desire to exercise their rights of co-sale with regard to such series of Preferred Stock.

 (iii) Each Investor may effect its participation in the sale of Common Stock by delivering to the Selling
Shareholder for transfer to the purchase offeror one or more certificates, properly endorsed for transfer, which represent: 
 (A) the number of shares of Common Stock that it elects to sell pursuant to this Section 3(b); or 
 (B) that number of shares of Preferred Stock that is at such time convertible into the number of shares of Common Stock that it has elected to sell pursuant to this Section 3(b); provided,
however, that if the purchase offeror objects to the delivery of Preferred Stock in lieu of Common Stock, such Investor may convert and deliver Common Stock as provided in subsection (i) above. 

(iv) Each Investor may effect its participation in the sale of Preferred Stock by delivering to the Selling Shareholder
for transfer to the purchase offeror one or more certificates, properly endorsed for transfer, which represent the number of shares of Permitted Preferred Co-Sale Shares that it elects to sell pursuant to this Section 3(b). 

(c) Payment of Proceeds. The stock certificates that the Investors deliver to the Selling
Shareholder pursuant to Section 3(b) shall be transferred by the Selling Shareholder to the purchaser in consummation of the sale of the Common Stock or Preferred Stock pursuant to the terms and conditions specified in the notice to the
Investors pursuant to Section 3(a), and the Selling Shareholder shall promptly thereafter remit to the Investors that portion of the sale proceeds to which the Investors are entitled by reason of their participation in such sale. To the
extent that any prospective purchaser or purchasers refuses to purchase shares or other securities from an Investor exercising its rights of co-sale hereunder, the Selling Shareholder shall not sell

  
 6

 
to such prospective purchaser or purchasers any Securities unless and until, simultaneously with such sale, the Selling Shareholder purchases such shares or other securities from such Investor
for the same consideration and on the same terms and conditions as the proposed transfer described in the Disposition Notice. 
 (d) Non-exercise. The exercise or non-exercise of the rights of the Investors hereunder to participate in one or more sales of Common Stock or Preferred Stock made by the
Selling Shareholder shall not adversely affect their rights to participate in subsequent Common Stock or Preferred Stock sales by any Selling Shareholder. 
 4. Drag-Along Rights. 
 (a)
Drag-Along Rights. If the holders of at least 65% of the outstanding shares of the Company’s capital stock (the “Selling Holders”) and the Company’s Board of Directors, shall approve the
sale of all or substantially all the assets or outstanding stock of the Company (whether structured as a merger, amalgamation, reorganization or otherwise), or any other transaction in which control of the Company is transferred, in one or a series
of bona fide arm’s length transactions (the “Sale”) to a third party (the “Buyer”), then such Selling Holders may require the Company to provide written notice of such approval (the
“Drag-Along Notice”) to Other Shareholders (as defined below), which shall be prepared in accordance with Section 4(c). The Sale must provide that holders of the Company’s capital stock shall receive the same
type and amount of consideration per share as is received by the other holders of the same series or class of capital stock; provided, however, if the consideration to be paid in connection with the Sale includes any securities and due receipt
thereof by a Shareholder would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities or (y) the provision to any Shareholder of
any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act of 1933, as amended, the Company
may cause to be paid to any such Shareholder in lieu thereof, against surrender of the capital stock which would have otherwise been sold by such Shareholder, an amount in cash equal to the fair value (as determined in good faith by the Board of
Directors) of the securities which such Shareholder would otherwise receive as of the date of the issuance of such securities in exchange for the capital stock. Upon the delivery of such Drag-Along Notice, each Selling Holder and Other Shareholder
shall be obligated to and shall: (a) sell, transfer and deliver, or cause to be sold, transferred and delivered, to such Buyer all of its shares of capital stock of the Company in the Sale at the closing thereof, including any shares issued or
issuable upon the exercise or conversion of any warrants, options, convertible securities or other rights to acquire any shares in the capital stock of the Company (the “Convertible Securities”) (and deliver certificates for
such issued shares at the closing, free and dear of all liens and encumbrances); (b) if shareholder approval of the Sale is required, vote all of its shares of capital stock of the Company, or provide an irrevocable proxy to vote its shares, in
favor thereof; and (c) not exercise any appraisal or dissenters’ rights to which such Other Shareholder or Selling Holder may be entitled. For purposes of this Agreement, the term “Other Shareholder”
refers to any Shareholder that is not a Selling Holder. 

  
 7

 (b) Drag-Along Notices. Each Drag-Along Notice
required to be prepared by Section 4(a) shall include reasonable details of the respective Sale including, but not limited to, the following: 
 (i) the proposed time and place of the closing of the Sale; 
 (ii)
the terms and conditions of the Sale including (i) the purchase price and terms of payment for the Selling Holders’ shares and (ii) the identity, beneficial ownership, address and telephone number of the Buyer having made the bona
fide offer; 
 (iii) the number and class of capital stock of the Company held by the Buyer and its affiliates
(if any), and details of any previous transactions under which the Buyer or any of its affiliates purchased capital stock of the Company from other Company shareholders; 

(iv) the number and class of the Selling Holders’ shares; and 

(v) a statement of intention to effect such a Sale, and that each of the Other Shareholders shall be entitled to sell any
or all of their shares of capital stock of any class (assuming convertible securities are fully exercised, as appropriate, prior to the consummation of the Sale) to the Buyer in conjunction with the closing of the Sale. 

(c) Conditions of Obligations of Shareholders. The obligations of the Shareholders pursuant to this
Section 4 are subject to the satisfaction of the following conditions: 
 (i) Upon the consummation
of a Sale (or as promptly as practicable in the case of certain options to purchase stock), the aggregate consideration received by the Shareholders shall be at least the same proportion of the aggregate consideration (excluding salaries, bonuses
and other compensation payable to employees of the Company) from such Sale that the Shareholders would have received if such aggregate consideration had been distributed by the Company in connection with a Liquidation Event pursuant to the rights
and preferences set forth in the Restated Certificate as in effect immediately prior to such Sale (giving effect to applicable orders of priority and the exercise price of all warrants and options); 

(ii) If other holders of the class or classes of capital stock held by the Shareholders are given an option as to the form
or amount of consideration to be received by such holders with respect to the class or classes of securities of the Company, all Shareholders will be given the same option with respect to such class or classes of securities; 

(iii) The Shareholders shall not be obligated to make any out-of-pocket expenditures prior to the consummation of the Sale
(costs incurred by or on behalf of a Shareholder for his sole benefit will not be considered an expenditure for purposes of this sentence) unless all stockholders are similarly responsible for their pro rata portion of such expenses; and 

(iv) In the event that the Shareholders are required to provide any representations or indemnities in connection with the
Sale (other than representations and indemnities concerning each Shareholder’s valid ownership of his shares of capital stock, free 

  
 8

 
and clear of all liens, claims and encumbrances (other than those arising under applicable securities laws), and each Shareholder’s power, authority, and right to enter into and consummate
such purchase, merger or similar agreement, in each case without violating any other agreement), then the Shareholders shall not be liable for more than their pro rata share (based upon the amount of consideration receivable) of any liability for
misrepresentation or indemnity and such liability shall not exceed the total purchase price received by the Shareholders for their shares of capital stock or options (including the exercise price thereof). 

5. Prohibited Transfers. 

(a) Grant. In the event the Selling Shareholder should sell or otherwise transfer any
Securities of the Company in contravention of (i) the first refusal rights of the Company and the Investors, as set forth above in Section 2, or (ii) the co-sale right of the Investors, as set forth above in
Section 3 (each, a “Prohibited Transfer”), the Investors shall have the put option provided in Section 5(b) with respect to the co-sale right and the option provided in Section 5(c) with
respect to the first refusal rights. 
 (b) Put Option. In the event of a Prohibited
Transfer involving the co-sale right, the Investors shall have the option to sell to the Selling Shareholder a number of shares of Common Stock (either directly or through delivery of Preferred Stock) or Preferred Stock of the Company equal to the
number of shares that the Investors would have been entitled to sell had such Prohibited Transfer been effected in accordance with Section 3 hereof, on the following terms and conditions: 

(i) The price per share at which the shares are to be sold to the Selling Shareholder shall be equal to the price per
share paid to the Selling Shareholder by the third-party purchaser or purchasers of the Selling Shareholder’s Securities. 
 (ii) The Investors shall deliver to the Selling Shareholder, within ninety (90) days after they have received notice from the Selling Shareholder or otherwise become aware of the Prohibited Transfer,
the certificate or certificates representing shares to be sold, each certificate to be properly endorsed for transfer. 
 (iii) The Selling Shareholder shall, upon receipt of the certificates for the repurchased shares, pay the aggregate purchase price therefor, by certified check or bank draft made payable to the order of
the Investors, and shall reimburse the Investors for any additional expenses, including legal fees and expenses, incurred in effecting such purchase and resale. 
 (c) First Refusal Prohibited Transfer. If any Selling Shareholder becomes obligated to sell any Target Shares to the Company or Investors (or fails to follow the procedures and terms of
Section 2 hereof) under this Agreement and fails to deliver such Target Shares in accordance with the terms of this Agreement, the Company and/or Investors may, at its option, in addition to all other remedies it may have, send to such
Selling Shareholder the purchase price for such Target Shares as is herein specified and transfer to the name of the Company or such Investors (or request that the Company effect such transfer in the name of it) on the Company’s books the
certificate or certificates representing the Target Shares to be sold. 

  
 9

 6. Legend Requirements. 

(a) Legend. Each certificate representing the Securities owned by a Shareholder shall be
endorsed with the following legend: 
 “THE SALE OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO
THE TERMS AND CONDITIONS OF A CERTAIN RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT, BY AND AMONG THE COMPANY, CERTAIN HOLDERS OF THE COMMON STOCK OF THE COMPANY AND THE HOLDERS OF THE PREFERRED STOCK OF THE COMPANY. A COPY OF SUCH AGREEMENT IS ON
FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. SUCH RIGHTS OF FIRST REFUSAL AND RIGHTS OF CO-SALE ARE BINDING ON THE TRANSFEREES OF SUCH SHARES.” 
 (b) Stop Transfer Instructions. In order to ensure compliance with the restrictions referred to herein, each Shareholder agrees that the Company may issue appropriate
“stop transfer” instructions. 
 (c) Transfers. No Securities shall be
transferred unless such transfer is made in compliance with applicable federal and state securities laws. The Company shall not be required (i) to transfer on its books any Securities that have been transferred in violation of any provision of
this Agreement or (ii) to treat as the owner of such Securities or to accord the right to vote as such owner or to pay dividends to any transferee to whom such Securities have been so transferred. Any proposed transfer not made in compliance
with the requirements of this Agreement shall be null and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company. 

(d) Removal. The legend in Section 6(a) above shall be removed upon termination of
this Agreement in accordance with the provisions of Section 7(a). 
 7. Miscellaneous.

 (a) Termination. This Agreement shall terminate at such time as the Investors
(together with their affiliates) shall no longer be the owner of any Securities. Unless sooner terminated in accordance with the preceding sentence, this Agreement shall terminate at the earliest to occur of: (i) immediately prior to the
closing of a “Qualified Public Offering” (as that term is defined in the Purchase Agreement); (ii) upon (A) the acquisition of the Company by means of any transaction or series of related transactions (including, without
limitation, any stock purchase transaction, merger, consolidation or other form of reorganization in which outstanding shares of the Company are exchanged for securities or other consideration issued, or caused to be issued, by the acquiring entity
or its subsidiary, but excluding (x) any transaction effected for the purpose of changing the Company’s jurisdiction of incorporation and (y) the sale by the Company of shares of its capital stock to investors in bona fide equity
financing transactions), unless securities representing more than fifty percent (50%) of the total combined 

  
 10

 
voting power of the voting securities of the surviving or acquiring entity or its direct or indirect parent entity are immediately thereafter beneficially owned, directly or indirectly and in
substantially the same proportion, by the Company’s shareholders of record as constituted immediately prior to such transaction or series of related transactions and (B) a sale of all or substantially all of the assets of the Company in a
single transaction or series of related transactions; or (iii) with the written consent of Shareholders holding at least a majority of the then-outstanding shares of (A) Series A Preferred Stock, acting together as a single class,
(B) Series B-l Preferred Stock, acting together as a single class, (C) Series C Preferred Stock, acting together as a single class, and (D) Series D Preferred Stock, acting together as a single class. 

(b) Notice. All notices and other communications hereunder shall be in writing
and shall be deemed given if delivered personally or by commercial delivery service, or mailed by registered or certified mail (return receipt requested) and sent via facsimile (with confirmation of receipt) or electronic mail to the parties at the
address for such party set forth here or, in the case of the Shareholders, as set forth on Schedules I and II hereof (or at such other address for a party as such party may designate pursuant to this
Section 7(b)): 
 (i) If to the Company: 

Whiteglove House Call Health, Inc. 

5300 Bee Cave Road 
 Building I, Suite 100 
 Austin, Texas 78746 

Fax: 512-266-7330 
 Attn: Chief Executive Officer 
 Email: bfabbio@housecallhealth.com

 with a copy (which shall not constitute notice) to: 

Andrews Kurth LLP 
 111 Congress Avenue, Suite 1700 
 Austin, Texas 78701 

Fax (512) 320-9292 
 Attn: Carmelo M. Gordian 
 (ii) If to an Investor, at the address
for such Investor set forth on Schedule I hereto. 
 (iii) If to the Common Shareholders at the
address for such Common Shareholder set forth on Schedule II hereto, with a copy to the Company as provided above. 
 Notice given by personal delivery, courier service or mail shall be effective upon actual receipt. Notice given by facsimile shall be shall be effective upon actual receipt if received during the
recipient’s normal business hours, or at the beginning of the recipient’s next business day after receipt if not received during the recipient’s normal business hours. All notices by facsimile shall be confirmed by the sender promptly
after transmission via certified mail or personal delivery. Any party may change any address to which notice is to be given to it by giving notice as provided above of such change of address. 

  
 11

 An electronic communication (“Electronic
Notice”) shall be deemed written notice for purposes of this Section 7(b) if sent with return receipt requested to the electronic mail address specified by the receiving party in a signed writing in a
nonelectronic form. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall be entitled to
receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”) which shall be sent to the requesting party within ten (10) days of receipt of the written request
for Nonelectronic Notice. 
 (c) Severability. If any provision of this Agreement
becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will
replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision.
The balance of this Agreement shall be enforceable in accordance with its terms. 
 (d)
Amendment. This Agreement may be altered, amended, waived or modified at any time only upon approval of such alteration, amendment, waiver or modification (each, an “Amendment”) by the written
consent of (i) the Company, and (ii) Shareholders holding at least a majority of the then-outstanding shares of (A) Series A Preferred Stock, acting together as a single class, (B) Series B-l Preferred Stock, acting together as a
single class, (C) Series C Preferred Stock, acting together as a single class, and (D) Series D Preferred Stock, acting together as a single class. The Company shall promptly notify the holders of each class of the Company’s voting
stock that an Amendment has been approved in accordance with the terms of this subsection. Any Amendment effected in accordance with this Section 7(d) shall be binding upon each Investor, each Common Shareholder and the Company.
Notwithstanding anything to the contrary in this Section 7(d), in the event of a subsequent closing with an investor as provided for in the Purchase Agreement, such investor shall become a party to this Agreement as an
“Investor” upon the Company’s receipt from such investor of an executed counterpart signature page to this Agreement, and such addition of an Investor, in such capacity, shall not be deemed to constitute an amendment hereof.
Notwithstanding anything to the contrary in this Section 6(d), additional holders of Common Stock may be added as parties to this Agreement as a “Common Shareholder” upon receipt from such holder of an executed counterpart
signature page to this Agreement, substantially in the form attached hereto as Exhibit B, and such addition of a Common Shareholder, in such capacity, shall not be deemed to constitute an amendment hereof. 

(e) Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of Texas, without regard to conflicts of law principles thereof. 
 (f)
Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary
disbursements in addition to any other relief to which such party may be entitled. 

  
 12

 (g) Further Assurances. Each party agrees to act
in accordance herewith and not to take any action that is designed to avoid the intention hereof. 
 (h)
Successors and Assigns. In addition to any restriction on transfer that may be imposed by any other agreement by which any party hereto may be bound, this Agreement shall be binding upon the Shareholders and their
respective permitted transferees, heirs, executors, administrators, successors and assigns (including transferees of any shares of Securities); provided, however, that the Company shall not effect any transfer of Securities subject to this
Agreement on its books or issue a new certificate for such Securities unless the transferee of such Securities shall have executed and delivered an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the
execution and delivery of an Adoption Agreement by any transferee, such transferee shall be deemed to be a party hereto as if such transferee’s signature appeared on the signature pages hereto. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties to this Agreement or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this
Agreement. 
 (i) Aggregation of Securities. For the purpose of exercising any rights
or taking any action under this Agreement, all shares of the Company’s Securities held or acquired by a Shareholder or its affiliates shall be aggregated together for the purpose of determining the availability of any rights under this
Agreement. For purposes of the foregoing, any Securities held by a Shareholder that (X) is a partnership, limited liability company or corporation shall be deemed to include shares held by (i) entities affiliated with such partnership,
limited liability company or corporation, (ii) any partner (or retired partner), member (or retired member) or shareholder of such partnership, limited liability company or corporation, (iii) the spouse, siblings, lineal descendants or
ancestors of any such partner (or retired partner), member (or retired member) or shareholder, (iv) the estate of any such partner (or retired partner), member (or retired member) or shareholder and (v) any custodian or trustee for the
benefit of any such partner (or retired partner), member (or retired member) or shareholder or the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or shareholder or (Y) is
an individual shall be deemed to include shares held by (i) the estate of such individual or (ii) the spouse, siblings, lineal descendants or ancestors of such individual and any custodian or trustee for the benefit of any of the foregoing
persons. Notwithstanding the foregoing, in the event that the holders of a particular series of Preferred Stock are entitled to exercise a right hereunder, the holders of that particular series of Preferred Stock who are a party to this Agreement
shall not be permitted to aggregate any other shares of Stock other than shares of that particular series of Preferred Stock for the purposes of determining the availability of such right under this Agreement. 

(j) Entire Agreement. This Agreement, including the schedules attached to this Agreement, and
the other documents delivered pursuant to this Agreement constitute the full and entire understanding and agreement among the parties with regard to the subject matter hereof and thereof, and no party shall be liable or bound to any other party in
any manner by any warranties, representations or covenants except as specifically set forth herein or therein. Each party hereto acknowledges and agrees that this Agreement amends and supersedes in their entirety all preceding agreements regarding
the subject matter hereof. 

  
 13

 (k) Conflict with Other Rights of First Refusal.
For so long as this Agreement remains in existence, the right of first refusal provisions contained in this Agreement shall supersede the right of first refusal provisions contained in any such Stock Restriction Agreement, Restricted Stock
Purchase Agreement, Stock Issuance Agreement or other similar agreement (“Purchase Agreements”) between the Company and a Common Shareholder; provided, however, that the other
provisions of such Purchase Agreements shall remain in full force and effect; and provided further, however, that the provisions of such Purchase Agreements with respect to the right of the Company to repurchase unvested shares held by such
Common Shareholder shall first be complied with before any such shares become subject to this Agreement. If, however, this Agreement shall terminate, the right of first refusal provisions contained in such Purchase Agreements shall have force and
effect as set forth in such agreements. 
 (1) Joint Product. This Agreement is the
joint product of the Company and the other parties hereto and each provision hereof and thereof has been subject to the mutual consultation, negotiation and agreement of the Company and the other parties hereto and shall not be construed against any
party hereto. 
 (m) Consent to Electronic Notice. Each Shareholder generally
consents to the delivery of any shareholder notice pursuant to the Texas Business Organizations Code (the “TBOC”), as amended or superseded from time to time, by electronic transmission at the electronic mail address or the
facsimile number set forth below such Shareholder’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given via electronic transmission is
returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have
been given. The Shareholders agree to promptly notify the Company of any change in such Shareholders electronic mail address, but failure to do so shall not affect the foregoing. 

(n) Counterparts. This Agreement may be executed in multiple counterparts, each of which shall
be deemed an original but all of which, when taken together, shall constitute one and the same instrument. 
 (o)
Specific Enforcement. It is agreed and understood that monetary damages would not adequately compensate an injured Shareholder for the breach of this Agreement by any party hereto, that this Agreement shall be
specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order. Further, the Company and each of the Shareholders waives any claim or
defense that there is an adequate remedy at law for such breach or threatened breach. 

  
 14

 (p) Delays or Omissions. Except as expressly
provided herein, no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach or default of another party under this Agreement, shall impair any such right, power or remedy of such party nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of
this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 (q) Interpretation. The words “include,” “includes” and
“including” when used herein shall be deemed in each case to be followed by the words “without limitation.” The titles and subtitles used in this Agreement are used for convenience only and are not considered in construing or
interpreting this Agreement. 
 (r) Telecopy Execution and Delivery. A facsimile,
telecopy or other reproduction of this Agreement may be executed by one or more parties to this Agreement, and an executed copy of this Agreement may be delivered by one or more parties to this Agreement by facsimile or similar electronic
transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party to this Agreement, all
parties to this Agreement agree to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction of this Agreement. 
 (s) Sale, Sell, Transfer, etc. The words “sale,” “sell,” “transfer,” and the like shall include any disposition by way of transfer with or without
consideration, to any persons for any purpose and include, without limitation, public or private offerings, exchanges, mergers, consolidations, reorganizations, redemptions, or any other transaction affecting the stock of the Company held by the
Common Shareholders and Investors. 
 (t) Ownership. Each Common Shareholder and each
Investor represents and warrants that, as of the date hereof, such Common Shareholder or Investor is the sole and legal owner, beneficially and of record, of the shares of stock subject to this Agreement and that no other person has any right, title
or interest (other than a community property interest) in such shares. 
 (u) Stock Splits, Stock
Dividends, etc. In the event of any stock split, stock dividend, recapitalization, reorganization, or the like, any securities issued with respect to the shares of Common Stock or Preferred Stock held by the Common Shareholders or
Investors shall become subject to the terms of this Agreement. 
 (v) Buy-Sell Agreement.
Reference is made to that certain Buy-Sell Agreement, as amended from time to time, by and between Robert Fabbio and William Rice; the parties acknowledge and agree that, to the extent there is a conflict, the terms and conditions of such
Buy-Sell Agreement shall control and supersede the terms and conditions of this Agreement. 

  
 15

 [Signature pages follow] 

  
 16

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Right
of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	COMPANY:
	
	WHITEGLOVE HOUSE CALL HEALTH, INC.
		
	By:	 	/s/ Robert A. Fabbio
		 	Robert A. Fabbio
		 	President and Chief Executive Officer

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Right
of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	IRA FBO Robert A. Fabbio Pershing LLC as Custodian Account Number: 5U9-986364
		
	By:	 	/s/ Robert A. Fabbio
		 	Robert A. Fabbio

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO 
 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND
CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Right
of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	TRAFLT, LLC
		
	By:	 	/s/ Robert A. Fabbio
		 	Manager

 WHITEGLOVE
HOUSE CALL HEALTH, INC. 
 SIGNATURE
PAGE TO 
 THIRD AMENDED AND RESTATED
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated
Right of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	/s/ William Rice
	William Rice

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO 
 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND
CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Right
of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	HQ INVESTORS 3, LLC
		
	By:	 	/s/ Lawrence Garatoni
		 	Lawrence Garatoni, Authorized Member

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO 
 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND
CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Right
of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	WR HAMBRECHT VENTURES II, L.P.
		
	By:	 	/s/ Alan Katz
	Name:	 	Alan Katz
	Title:	 	Manager

 WHITEGLOVE
HOUSE CALL HEALTH, INC. 
 SIGNATURE
PAGE TO 
 THIRD AMENDED AND RESTATED
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Right
of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	HIDDEN LION PARTNERS I, LLC
		
	By:	 	Hidden Lion Partners Management Company, LLC, its Managing Director
		
	By:	 	/s/ Mark Sherman
		 	Mark Sherman, Managing Director

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO 
 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND
CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated
Right of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	ENHANCED EQUITY FUND II, L.P.
		
	By:	 	EEF Partners II LLC, its General Partner
		
	By:	 	/s/ Malcolm T. Kostuchenko
		 	Malcolm T. Kostuchenko, Managing Partner
	
	EEF II CO-INVEST LLC
		
	By:	 	/s/ Andrew M. Paul
		 	Andrew M. Paul, Sole Member

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated
Right of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

	
	COMMON SHAREHOLDERS:
	
	/s/ Robert A. Fabbio
	Robert A. Fabbio

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO 
 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND
CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated
Right of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

	
	COMMON SHAREHOLDERS:
	
	/s/ William Rice
	William Rice

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO 
 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND
CO-SALE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated
Right of First Refusal and Co-Sale Agreement as of the date first set forth above. 
  

	
	COMMON SHAREHOLDERS:
	
	/s/ Jimmy Treybig
	Jimmy Treybig

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO THIRD AMENDED AND
RESTATED VOTING AGREEMENT 

 SCHEDULE I 

Schedule of Investors 
  

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 IRA FBO “Robert A. Fabbio”
 c/o Pershing, LLC
 One Pershing Plaza
 Jersey City, NJ 07399
	  				  	 	68,302	  	  	 	113,837	  	  				  			
						
	 TRAFLT, LLC
 215 Bella
Riva
 Austin, Texas 78734
 Fax:
512-266-7330
	  	 	2,216,667	  	  	 	32,448	  	  				  				  			
						
	 Monica Fabbio
 215 Bella
Riva Austin, Texas 78734
 Fax: 512-266-7330
	  				  	 	40,000	  	  				  				  			
						
	 Wilson G. Allen
 403
Buckeye Trail
 Austin, Texas 78746

wilson@westlakellc.com
	  				  	 	50,000	  	  				  				  			
						
	 Rudge Allen Investment Company
 403 Buckeye Trail
 Austin. Texas 78746
 wilson@westlakellc.com
	  				  	 	25,000	  	  				  				  			
						
	 Eric Rothfus
 4
Coleridge Lane
 Austin, Texas 78746

eric.rothfus@guggenheimpartners.com
	  				  	 	50,000	  	  				  				  			
						
	 Ed Ateyeh
 4410 Michaels
Cove
 Austin, Texas 78746

taylor@colltech.com
	  				  	 	50,000	  	  	 	22,767	  	  				  			
						
	 Laura J. Kilcrease
 7504
Clove Cove
 Austin, Texas 78750
 Fax:
512-346-0082
 laura@tritonventures.com
	  				  	 	25,000	  	  	 	11,383	  	  				  			
						
	 Famiglia Ciola, LLC
 803
Hurst Creek Road
 Austin, Texas 78734

dciola@asglp.com
	  				  	 	50,000	  	  				  	 	14,632	  	  			
						
	 Paul Twitchell
 2011
Crosby Road
 Wayzata, Minnesota 55391

ptwitchell@whiteboxadvisors.com
	  				  	 	50,000	  	  	 	45,535	  	  				  			
						
	 Meredith Family Revocable Trust
 248 Addie Roy Road, Suite C-200
 Austin TX 78742

Fax: 512-732-0225
	  				  	 	266,600	  	  	 	190,000	  	  	 	61,282	  	  			

 Schedule I 

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 JMM PTLP Ltd.
 c/o Randy
McFadden
 Telephone Management
 609
Castle Ridge Road, Suite 215
 Austin, Texas 78746
 512-327-4454
 (fax) 512-327-5561
 rmcfadden@telephonemanagement.com
	  				  	 	125,000	  	  				  				  			
						
	 Nicholas J. Nascone
 217
Bella Riva
 Austin, Texas 78734

512-413-3657
 nick@nascone.com
	  				  	 	25,000	  	  	 	11,384	  	  				  			
						
	 Jeffrey S. Muir
 Fulcrum
Ventures
 1040 Crown Pointe Parkway, Suite 330
 Atlanta, Georgia 30338
 770-551-6300
 (fax) 770-551-6330
	  				  	 	12,500	  	  				  				  			
						
	 William Rice
 3601
Travis County Circle
 Austin, Texas 78735
 brice@housecallhealth.com
	  	 	1,108,333	  	  	 	1,350	  	  				  				  			
						
	 Michael Hancock
 3701
Whitt Loop
 Austin, Texas 78749

512-422-3093

mhancock@housecallhealth.com
	  				  	 	2,652	  	  				  	 	776	  	  			
						
	 HQ Investors 3, LLC

Anthony Wright
 1150 Lakeway Drive, Suite
207
 Austin, TX 78734

tony.wright@hqinvestments.com
	  				  				  	 	684,655	  	  	 	199,166	  	  			
						
	 W. W. McAllister III

4940 Broadway #305
 San Antonio, TX
78209
 bomcallister@sbcglobal.net
	  				  				  	 	68,302	  	  				  			
						
	 Three Lee Investments Limited
 970 Isom Road
 San Antonio, TX 78209
 Fax: 866-511-1249
 slee@qlee.net
	  				  				  	 	136,604	  	  				  			
						
	 Andrews Kurth LLP
 111
Congress Ave., Suite 1700
 Austin, Texas 78701
 Attn: Carmelo M. Gordian
 Fax: 512-320-9292
	  				  				  	 	6,830	  	  				  			
						
	 St. James’s Park Ventures, LP
 3801 N. Capital of Texas Highway
 Suite E-240, #62

Austin, TX 78746

steve@sjpholding.com
	  				  				  	 	45,535	  	  	 	61,282	  	  			

 Schedule I 

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 Will McAlister

4940 Broadway #305

San Antonio, TX 78209

Fax: 210-824-7028
	  				  				  	 	22,767	  	  				  			
						
	 WR Hambrecht Ventures II, L.P.

Margo Ranucci
 WR Hambrecht + Co
 Private Equity

Administrator/Compliance

Administrator
 Pier l, Bay 3
 San Francisco, CA 94111

Tel. (415) 551-8649

Fax: (415) 551-8625

mranucci@wrhambrecht.com
	  				  				  	 	387,049	  	  				  			
						
	 Spersibs, LP

5300 Bee Cave Road

Bldg 1-220
 Austin, TX 78746
 Phil@psper.com
	  				  				  	 	20,400	  	  	 	13,727	  	  			
						
	 Accent Texas Fund II, L.P.

5300 Bee Caves Road

Building 1, Suite 240

Austin, TX 78746
 Attention: Mansoor Ghori
 Fax: 5120306-9967

mansoororg@accentcap.com
	  				  				  				  	 	76,603	  	  			
						
	 Hidden Lion Partners I, LLC

Attn: Mark Sherman

2506 Union Street

San Francisco , CA 94123

Tel. (415) 734-1977

Fax: (415) 996-3355

mark@hiddenlion.com
	  				  				  				  	 	1.532,050	  	  			
						
	 Enhanced Equity Fund II, L.P.

Attn: Malcolm T. Kostuchenko

601 Lexington Avenue, 55th Floor
 New York, NY 10022
 Fax: 212-207-3386
	  				  				  				  				  	 	2,182,858	  
						
	 EEF II Co-Invest LLC

Attn: Malcolm T. Kostuchenko

601 Lexington Avenue, 55th Floor
 New York, NY 10022
 Fax: 212-207-3386
	  				  				  				  				  	 	133,619	  
						
	 Enhanced Capital Texas Fund II, LLC

Attn: Paul Kasper

601 Lexington Avenue, 55th Floor
 New York, NY 10022
 Fax: 212-207-3386
	  				  				  				  	 	153,205	  	  			

 Schedule I 

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 Andrew M. Paul

283 Pondfieid Road

Bronxville, NY 10708

Fax: 212-207-3386

apaul@enhancedcap.com
	  				  				  				  	 	153,205	  	  			
						
	 Jonathon Kaiden

515 W. 52nd Street
 Apartment PHIF
 New York, NY 10019

Fax: 212-207-3386

jkaiden@enhancedcap.com
	  				  				  				  	 	7,660	  	  			
						
	 Barry Osherow

32 South Bedford Rd.

Pound Ridge, NY 10576

bosherow@yahoo.com
	  				  				  				  	 	3,064	  	  			
						
	 Paul S. Kasper

161 Hudson Street

Apt #2C
 New York, NY 10013
	  				  				  				  	 	7,660	  	  			
						
	 Michael Korengold

10 Dellwood Circle 

Bronxville, NY 10708

Fax: 212-207-3386

mkorengold@enhancedcap .com
	  				  				  				  	 	4,596	  	  			
		  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 TOTAL
	  	 	3,325,000	  	  	 	873,852	  	  	 	1,767,048	  	  	 	2,288,908	  	  	 	2,316,477	  
		  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 

 Schedule I 

 SCHEDULE II 

Schedule of Common Shareholders 
  

					
	 Name/Address
	  	Common Shares	 
	 Robert A. Fabbio

215 Bella Riva
 Austin, Texas 78734
 Fax: 512-266-7330

Email: bob@fabbio.com
	  	 	33,814	  
		
	 William Rice

3601 Travis County Circle

Austin, Texas 78735

brice@housecallhealth.com
	  	 	16,186	  
		
	 Danny Bone

130 Walnut Tree Loop

Georgetown TX 78633
	  	 	12,000	  
		
	 Sebastian Brocher

7313 Rimcrest Cove

Austin TX 78735
	  	 	43,496	  
		
	 George Catlin

5304 Wishek Cove
 Austin TX 78730
	  	 	6,000	  
		
	 Richard Willis

2701 Regents Park

Austin TX 78746
	  	 	30,500	  
		
	 Kylie Jordan Bruehler Irrevocable Trust
	  	 	5,000	  
		
	 Majin Castillo

1300 Annie Lane
 Libertyville, IL 60048
	  	 	7,500	  
		
	 Donnie Hromadka

3104 Fort Worth Trail

Austin TX 78748
	  	 	10,000	  
		
	 Jimmy Treybig

10915 Bee Caves Road

Austin TX 78733
	  	 	39,000	  
		  	 	 	 
	 Total
	  	 	203,496	  
		  	 	 	 

 Schedule II 

  

 EXHIBIT A 

ADOPTION AGREEMENT 
 This Adoption Agreement (“Adoption Agreement”) is executed by the undersigned (the “Transferee”) pursuant to the
terms of that certain Third Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of March 2, 2011 (the “Agreement”) by and among Whiteglove House Call Health, Inc., a Texas corporation
(the “Company”), the Investors and the Common Shareholders. Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this
Adoption Agreement, the Transferee agrees as follows: 
 1. Acknowledgement. Transferee acknowledges
that Transferee is acquiring certain shares of the capital stock of the Company (the “Stock”), which shares are subject to the terms and conditions of the Agreement. 

2. Agreement. As partial consideration for such transfer, Transferee (i) agrees that the Stock acquired
by Transferee shall be bound by and subject to the terms of the Agreement, to the same extent and with the same rights and obligations as the person(s) from which such Stock is received and (ii) hereby agrees to become a party to the Agreement
with the same force and effect as if Transferee were originally a party thereto. 
 3. Notice. Any
notice required or permitted by the Agreement shall be given to Transferee at the address listed below Transferee’s signature below. 
 4. Joinder. The spouse of the undersigned Transferee, if applicable, executes this Adoption to acknowledge its fairness and that it is in such spouse’s best interests and to bind to the
terms of the Agreement such spouse’s community interest, if any, in the Stock. 
 EXECUTED AND DATED this
         day of                     ,         .

  

			
	TRANSFEREE:
	
	 
	Title:	 	 
	Address:	 	 
	Fax:	 	 
		 	
	Spouse: (if applicable):
	
	 
	Name:	 	 

 Acknowledged and accepted on
                    ,         . 

 

			
	WHITEGLOVE HOUSE CALL HEALTH, INC.
		
	By:	 	 
		 	Robert A. Fabbio
		 	Chief Executive Officer

 Exhibit A

  

 EXHIBIT B 

SIGNATURE PAGE TO WHITEGLOVE HOUSE CALL HEALTH, INC. 
 THIRD AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE 
 AGREEMENT

 The undersigned hereby executes, delivers and agrees to become a party as a Common Shareholder under the Third Amended
and Restated Right of First Refusal and Co-Sale Agreement dated March 2, 2011 (the “Agreement”). Schedule II to the Agreement is hereby amended to add the Common Shareholder as set forth
below. 
 EXECUTED AND DATED this          day of
                    ,         . 

 

									
		 		 	
			
	[signature block for entities]	 		 	 
		 		 		 	(Print Name of Entity)
		 		 		 	
		 		 		 	By:	 	 
		 		 		 	Name:	 	 
		 		 		 	Title:	 	 

  

									
		 		 	
			
	[signature block for individuals]	 		 	 
		 		 		 	(Signature)
		 		 		 	
		 		 		 	 
		 		 		 	(Print Name of Individual)
		 		 		 	
		 		 		 	Address:	 	 
		 		 		 	 
		 		 		 	Fax:	 	 

 Acknowledged and accepted on
                    ,              

 

			
	WHITEGLOVE HOUSE CALL HEALTH, INC,
		
	By:	 	 
	Name:	 	Robert A. Fabbio
	Title:	 	Chief Executive Officer

 Exhibit BThird Amended and Restated Voting Agreement

 Exhibit 4.4 
 WHITEGLOVE HOUSE CALL HEALTH, INC. 
 THIRD AMENDED AND RESTATED VOTING
AGREEMENT 
 THIS THIRD AMENDED AND RESTATED VOTING AGREEMENT (the “Agreement”) is made as of
March 2, 2011, by and among Whiteglove House Call Health, Inc., a Texas corporation (the “Company”), the parties listed as “Investors” on Schedule I hereto (each, an
“Investor” and collectively, the “Investors”), and each of the parties listed as “Common Shareholders” on Schedule II hereto (each, a “Common
Shareholder” and collectively, the “Common Shareholders”). The Investors and Common Shareholders are sometimes referred to herein individually as a “Shareholder” and collectively as the
“Shareholders.” 
 RECITALS: 

WHEREAS, the Company and certain of the Investors have entered into a Series D Preferred Stock Purchase Agreement dated as of even
date herewith (the “Purchase Agreement”) by and among the Company and the Investors named therein, providing, among other things, for the purchase of shares of the Company’s Series D Convertible Preferred Stock, par
value $0.01 per share (the “Series D Preferred Stock”); 
 WHEREAS, the Company’s and such
Investors’ respective obligations under the Purchase Agreement are conditioned upon the execution and delivery of this Agreement; 
 WHEREAS, the Company’s Seventh Amended and Restated Certificate of Formation (as amended from time to time, the “Restated Certificate”) provides (i) for so long as
any shares of Preferred Stock remain outstanding the holders of Preferred Stock, voting or acting together as a single class, shall be entitled to elect four (4) directors, and (ii) additional members of the Board of Directors shall be
elected by the vote of the holders of Common Stock and Preferred Stock, voting or acting together as a single class; and 

WHEREAS, in connection with the consummation of the transactions contemplated by the Purchase Agreement, the Company and the
Shareholders have agreed to provide for the future voting of their shares of the capital stock of the Company as set forth herein. 
 AGREEMENT: 
 NOW, THEREFORE, in consideration of the
foregoing premises, the mutual promises and agreements contained herein, and certain other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

1. Definitions. For purposes of this Agreement, the following definitions shall apply: 

“Affiliate” of a Shareholder shall mean any person that controls, is controlled by, or is under
common control with, or is otherwise affiliated with such Shareholder. 

  
 1 

 “Preferred Stock” shall mean the Company’s Series
A Convertible Preferred Stock, par value $0.01 per share, the Company’s Series A-l Convertible Preferred Stock, par value $0.01 per share (and together with the Company’s Series A Convertible Preferred Stock, the “Series A
Preferred Stock”), the Company’s Series B-l Convertible Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), the Company’s Series C Convertible Preferred Stock, par value $0.01
per share (the “Series C Preferred Stock”), and the Series D Preferred Stock. 

“Stock” shall mean any and all shares of voting stock of the Company, including but not limited to
the Common Stock and the Preferred Stock, (i) that are now or hereafter owned (either beneficially or otherwise) by a Shareholder, and (ii) that a Shareholder does not own (either beneficially or otherwise) but as to which such Shareholder
has voting power. In the event that any provision of this Agreement calls for a vote of a specified percentage of the stock, such specified percentage shall be determined on an as-converted basis. 

2. Composition of Board of Directors. Each Shareholder agrees that in any election of directors of the
Company, each Shareholder shall vote all shares of Stock owned or controlled by such Shareholder (or shall consent pursuant to an action by written consent of the holders of capital stock of the Company), including all shares that each Shareholder
is entitled to vote under any voting trust, voting agreement, proxy or other arrangement, to elect a Board of Directors composed of six (6) members, designated as follows: 

(a) Preferred Directors. At each election of or action by written consent to elect directors in which the holders
of Preferred Stock are entitled to elect directors of the Company: 
 (i) one director (the “Series A
Director”) designated by the holders of a majority of the shares of Series A Preferred Stock, voting together as a single class, such Series A Director initially being William Rice; 

(ii) one director (the “Series B Director”) designated by the holders of a majority of the shares
of Series B Preferred Stock, voting together as a single class, such Series B Director initially being Larry Garatoni; 
 (iii) one director (the “Series C Director”) designated by the holders of a majority of the shares of Series C Preferred Stock, voting together as a single class, such Series C
Director initially being Mark Sherman; and 
 (iv) one director (the “Series D Director”)
designated by the holders of a majority of the shares of Series D Preferred Stock, voting together as a single class, such Series D Director initially being Malcolm T. Kostuchenko. 

The Series A Director, Series B Director, Series C Director and Series D Director shall be referred to herein collectively as the
“Preferred Directors”. 

  
 2 

 (b) Additional Directors. At each election of directors in which the
holders of Common Stock and the holders of Preferred Stock, voting together as a single class, are entitled to elect directors of the Company: 
 (i) one director who is the Company’s Chief Executive Officer (or, if there is not a Chief Executive Officer, then the President of the Company) (the “CEO Director”), such CEO
Director initially being Robert A. Fabbio; and 
 (ii) one director designated unanimously by the Preferred
Directors and the CEO Director (the “At-Large Director”), such At-Large Director initially being James Treybig. 
 In the absence of any designation from the persons or groups with the right to designate a director as specified above, the director previously designated by them and then serving shall be re-elected if
still eligible to serve as provided herein. 
 (c) Observer Rights. 

(i) As long as HQ Investors 3, LLC (together with its Affiliates, “HQ”) holds any shares of
Preferred Stock and does not otherwise have a representative on the Company’s Board of Directors, the Company shall invite a representative of HQ to attend all meetings of the Board of Directors in a non-voting capacity and, in this respect,
shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors; provided that such representative shall, upon the Company’s request, agree in writing to hold in confidence
and trust all information so provided; and provided further that the Company reserves the right to exclude such individual from access to any of such materials or meetings or portions thereof if (i) the Board of Directors believes upon
advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege or confidential information or (ii) a majority of the directors of the Company reasonably believes that such access would or could
materially impair the due consideration by the Board of Directors of any specific matter. 
 (ii) As long as
Meredith Family Revocable Trust (together with its Affiliates, “MFRT”) holds any shares of Preferred Stock and does not otherwise have a representative on the Company’s Board of Directors, the Company shall invite a
representative of MFRT to attend all meetings of the Board of Directors in a non-voting capacity and, in this respect, shall give such representative copies of all notices, minutes, consents and other materials that it provides to its directors;
provided that such representative shall, upon the Company’s request, agree in writing agree to hold in confidence and trust all information so provided; and provided further that the Company reserves the right to exclude such
individual from access to any of such materials or meetings or portions thereof if (i) the Board of Directors believes upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege or confidential
information or (ii) a majority of the directors of the Company reasonably believes that such access would or could materially impair the due consideration by the Board of Directors of any specific matter. 

3. Grant of Proxy. To ensure the performance of each Shareholder with respect to the agreements set forth herein, each
Shareholder hereby appoints the Chairman of the Board of Directors and the Chief Executive Officer of the Company, or either of them from time to time, or their designees, as his, her or its true and lawful proxy and attorney-in-fact, with full
power of substitution and resubstitution, to vote all Stock owned or held by such Shareholder and to 

  
 3 

 
execute all appropriate instruments consistent with this Agreement, subject to the provisions of this Agreement, upon any matter presented to the shareholders of the Company, if and only if such
Shareholder fails to vote all of such Shareholder’s Stock or execute such other instruments in accordance with the provisions of this Agreement within five (5) days of the Company’s or any other party’s written request for such
Shareholder’s written consent or signature. The proxies and powers granted by each Shareholder pursuant to this Section 3 are coupled with an interest and are given to secure the performance of such Shareholder’s commitments
under this Agreement. Such proxies shall be irrevocable for the term of this Agreement and shall survive the death, incompetence, disability, merger, reorganization, dissolution or winding up of such Shareholder. Except as provided above, no
Shareholder shall grant a proxy with respect to, transfer any voting control over, or create any right to vote any shares of Stock of the Company without the prior written consent of the Company. 

4. Subsidiary Governing Bodies. Unless otherwise mutually agreed to by (i) the holders of at least sixty-five percent
(65%) of the shares of Stock subject hereto voting together as a single class, (ii) the holders of a majority of the shares of Series A Preferred Stock voting together as a single class, (iii) the holders of a majority of the shares
of Series B Preferred Stock voting together as a single class, (iv) the holders of a majority of the shares of Series C Preferred Stock voting together as a single class, (v) the holders of a majority of the shares of Series D Preferred
Stock voting together as a single class, and (vi) the Company, the members of the Board of Directors, as the same shall be constituted from time to time, shall also constitute the board of directors or equivalent governing body of each
subsidiary of the Company. 
 5. Vote to Increase Authorized Common Stock. Each Shareholder agrees to vote or
cause to be voted all shares of Stock owned by such Shareholder, or over which such Shareholder has voting control, from time to time and at all times, in whatever manner, as long as it is consistent with the Restated Certificate, as shall be
necessary to increase the number of authorized shares of Common Stock from time to time to ensure that there will be sufficient shares of Common Stock available for conversion of all of the shares of Preferred Stock outstanding at any given time.

 6. Obligations of the Company. The Company shall use its best efforts and shall exercise all authority under
applicable law to cause to be nominated for election and cause to be elected or appointed, as the case may be, as directors of the Company, a slate of directors consisting of individuals meeting the requirements of Section 2. The Company
will not, by any voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all of the provisions of this
Agreement and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Investors hereunder against impairment. Each Shareholder hereby agrees to vote, cause to be voted or sign a written consent with
respect to all of its shares in favor of a slate of directors consisting of individuals meeting the requirements of Section 2. 
 7. Vacancies; Removal. In the event of any vacancy in the Board of Directors, each Shareholder agrees to vote all outstanding shares of Stock owned or controlled by such Shareholder and to
use such Shareholder’s best efforts to fill such vacancy so that the Board of Directors will be comprised of directors designated as provided in Section 2. Each Shareholder 

  
 4 

 
agrees to vote all outstanding shares of Stock owned or controlled by such Shareholder for the removal of a director whenever (but only whenever) there shall be presented to the Board of
Directors the written direction that such director be removed, signed by: (i) the holders of a majority of the shares of Series A Preferred Stock, voting together as a single class, in the case of the Series A Director, (ii) the holders of
a majority of the shares of Series B Preferred Stock, voting together as a single class, in the case of the Series B Director, (iii) the holders of a majority of the shares of Series C Preferred Stock, voting together as a single class, in the
case of the Series C Director, (iv) the holders of a majority of the shares of Series D Preferred Stock, voting together as a single class, in the case of the Series D Director, and (v) the Preferred Directors and the CEO Director, in the
case of the At-Large Director. In any such event, the Board of Directors shall solicit the vote of the Shareholders entitled to remove such director in order to effect such removal. In addition, in the event that the person serving as the CEO
Director ceases to serve as the Company’s Chief Executive Officer or President, as the case may be, the Shareholders agree to vote all outstanding shares of Stock owned or controlled by them for the removal of such CEO Director at the request
of a majority of the Board of Directors (excluding the CEO Director). 
 8. Indemnification Agreements and D&O
Insurance. 
 (a) As of the date that any person is first elected or appointed to the Board of Directors,
the Company shall enter into an indemnification agreement in substantially the form attached as Exhibit A hereto with such person. 
 (b) The Company shall use its commercially reasonable efforts to obtain, within one hundred twenty (120) calendar days of the date hereof, from financially sound and reputable insurers, directors and
officers insurance with coverage customary for companies similarly situated to the Company, except as otherwise decided in accordance with policies adopted by the Company’s Board of Directors (including the approval or consent of a majority of
the Preferred Directors). The Company will use commercially reasonable efforts to maintain the directors and officers insurance required by this Section 8, except as otherwise decided in accordance with policies adopted by the
Company’s Board of Directors (including the approval or consent of a majority of the Preferred Directors). Such policy shall not be cancelable by the Company without prior approval of the Board of Directors (including the approval or consent of
a majority of the Preferred Directors). 
 9. Expenses. The Company shall reimburse all members of
its Board of Directors who are not employees of the Company for all reasonable out of pocket expenses related to meetings of the Board of Directors. 
 10. No Liability for Election of Recommended Directors. No Shareholder, nor any Affiliate of any Shareholder, shall have any liability as a result of designating a person for election as a
director or for any act or omission by such designated person in his or her capacity as a director of the Company, nor shall any Shareholder have any liability as a result of voting for any such designee in accordance with the provisions of this
Agreement. 

  
 5 

 11. Legend. The Shareholders agree that each certificate of each of the
Company’s classes of stock held of record by the Shareholders shall bear a legend (which shall be made conspicuous by using capital letters, bold-face or contrasting type, underlining or by similar means) in substantially the following form:

 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO A VOTING AGREEMENT, A COPY OF WHICH HAS BEEN DEPOSITED WITH
THE COMPANY AT ITS PRINCIPAL OFFICE AND WILL BE PROVIDED TO THE HOLDER HEREOF UPON REQUEST.” 
 The Company consents and
agrees to the placement of such legend on certificates evidencing stock of any of the Company’s classes of stock issued to a Shareholder and agrees to endorse the foregoing legends on such certificates and to notify any potential transferee of
a Shareholders’ shares of stock of this Agreement. 
 12. Termination. This Agreement shall
terminate at such time as the Investors (together with their Affiliates) shall no longer be the owner of any Stock. Unless sooner terminated in accordance with the preceding sentence, this Agreement shall terminate at the earliest to occur of:
(i) immediately prior to the closing of a firm underwritten initial public offering of Common Stock under the Securities Act; (ii) upon (A) the acquisition of the Company by means of any transaction or series of related transactions
(including, without limitation, any stock purchase transaction, merger, consolidation or other form of reorganization in which outstanding shares of the Company are exchanged for securities or other consideration issued, or caused to be issued, by
the acquiring entity or its subsidiary, but excluding (x) any transaction effected for the purpose of changing the Company’s jurisdiction of incorporation and (y) the sale by the Company of shares of its capital stock to investors in
bona fide equity financing transactions, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the surviving or acquiring entity or its direct or indirect parent entity are
immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the Company’s shareholders of record as constituted immediately prior to such transaction or series of related transactions and
(B) a sale of all or substantially all of the assets of the Company in a single transaction or series of related transactions; or (iii) with the written consent of the Investors holding at least (A) sixty-five percent (65%) of
the shares of Stock subject hereto, (B) a majority of the shares of Series A Preferred Stock voting together as a single class, (C) a majority of the shares of Series B Preferred Stock voting together as a single class, (D) a majority
of the shares of Series C Preferred Stock voting together as a single class, and (E) a majority of the shares of Series D Preferred Stock voting together as a single class. 

13. Miscellaneous. 
 (a) Binding Effect. In addition to any restriction on transfer that may be imposed by any other agreement by which any party hereto may be bound, this Agreement shall be binding upon the
Shareholders and their respective permitted transferees, heirs, executors, administrators, successors and assigns; provided, however, that the Company shall not effect any transfer of Stock subject to this Agreement on its books or issue a
new certificate for such Stock unless the transferee of such Stock shall have executed and delivered an Adoption Agreement substantially in the form attached hereto as Exhibit B. Upon the execution and delivery of an Adoption Agreement
by any transferee, such transferee shall be deemed to be a party hereto as if 

  
 6 

 
such transferee’s signature appeared on the signature pages hereto. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties to this
Agreement or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

(B) Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF TEXAS, WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES THEREOF. 
 (c)
Severability. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the
extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic,
business and other purposes of the illegal, void or unenforceable provision. The balance of this Agreement shall be enforceable in accordance with its terms. 
 (d) Entire Agreement. This Agreement, including the schedules attached to this Agreement, and the other documents delivered pursuant to this Agreement constitute the full and
entire understanding and agreement among the parties with regard to the subject matter hereof and thereof, and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically
set forth herein or therein. Each party hereto hereby acknowledges and agrees that this Agreement amends and supersedes in their entirety all preceding agreements regarding the subject matter hereof. 

(e) Amendments. This Agreement may be altered, amended, waived or modified at any time only
upon approval of such alteration, amendment, waiver or modification (each, an “Amendment”) by the written consent of (i) the Company, (ii) Shareholders holding a majority of the shares of Series A Preferred Stock
voting together as a single class, (iii) Shareholders holding a majority of the shares of Series B Preferred Stock voting together as a single class, (iv) Shareholders holding a majority of the shares of Series C Preferred Stock voting
together as a single class, and (v) Shareholders holding a majority of the shares of Series D Preferred Stock voting together as a single class; provided, however, that any Amendment affecting a Shareholder’s right to designate a
director of the Company or a Shareholder’s board observer right pursuant to Section 2 hereof shall not be binding unless the Shareholder or Shareholders holding a majority of such shares of voting stock entitled to designate such
director or provide a board observer has agreed in writing to such Amendment; provided further, that any Amendment which would disproportionately and adversely affect any one Shareholder relative to the other Shareholders must be approved by
such disproportionately affected Shareholder. The Company shall promptly notify the holders of each class of the Company’s voting stock that an Amendment has been approved in accordance with the terms of this subsection. Any Amendment effected
in accordance with this Section 13(e) shall be binding upon each Investor, each Common Shareholder and the Company. Notwithstanding anything to the contrary in this Section 13(e), in the event of a subsequent closing with an
investor as provided for in the Purchase Agreement, such investor shall become a party to this Agreement as an “Investor” upon the Company’s receipt from such investor of an executed counterpart signature page to this Agreement, and
such addition of an Investor, in such capacity, shall not be 

  
 7 

 
deemed to constitute an amendment hereof. Notwithstanding anything to the contrary in this Section 13(e), additional holders of Common Stock may be added as parties to this Agreement
as a “Common Shareholder” upon receipt from such holder of an executed counterpart signature page to this Agreement, substantially in the form attached hereto as Exhibit C, and such addition of a Common Shareholder, in such
capacity, shall not be deemed to constitute an amendment hereof. 
 (f) Notices. All
notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally, by commercial delivery service, mailed by registered or certified mail (return receipt requested), sent via facsimile (with
confirmation of receipt) or electronic mail to the parties at the address for such party set forth herein (or at such other address for a party as such party may designate pursuant to this Section 13(f)): 

(i) If to the Company: 
      Whiteglove House Call Health, Inc. 

     5300 Bee Cave Road 

     Building I, Suite 100 

     Austin, Texas 78746 

     Fax: 512-266-7330 

     Attn: Robert A. Fabbio 

     Email: bfabbio@housecallhealth.com 

     with a copy (which shall not constitute notice) to: 

     Andrews Kurth LLP 

     111 Congress Avenue, Suite 1700 

     Austin, Texas 78701 

     Fax: 512-320-9292 

     Attn: Carmelo M. Gordian 

     Email: carmelogordian@akllp.com 

(ii) If to an Investor, at the address for such Investor set forth on Schedule I hereto. 

(iii) If to the Common Shareholders, at the address for such Common Shareholder set forth on Schedule II
hereto. 
 Notice given by personal delivery, courier service or mail shall be effective upon actual receipt. Notice
given by facsimile shall be effective upon actual receipt if received during the recipient’s normal business hours, or at the beginning of the recipient’s next business day after receipt if not received during the recipient’s normal
business hours. All notices by facsimile shall be confirmed by the sender promptly after transmission by the sender in writing by certified mail or personal delivery. Any party may change any address to which notice is to be given to it by giving
notice as provided above of such change of address. 

  
 8 

 An electronic communication (“Electronic Notice”) shall be deemed
written notice for purposes of this Section 13(f) if sent with return receipt requested to the electronic mail address specified by the receiving party in a signed writing in a nonelectronic form. Electronic Notice shall be deemed
received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form
(“Nonelectronic Notice”) which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice. 

(g) Consent to Electronic Notice. Each Shareholder generally consents to the delivery of any shareholder
notice pursuant to the Texas Business Organizations Code, as amended or superseded from time to time, by electronic transmission at the electronic mail address or the facsimile number set forth below such Shareholder’s name on the Schedules
hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given via electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to
have been revoked until a new or corrected electronic mail address has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have been given. The Shareholders agree to promptly notify the Company of any change in
such Shareholders electronic mail address, but failure to do so shall not affect the foregoing. 
 (h)
Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original but all of which, when taken together, shall constitute one and the same instrument. 

(i) Specific Enforcement. It is agreed and understood that monetary damages would not adequately compensate
an injured Shareholder for the breach of this Agreement by any party hereto, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent
injunction or restraining order. Further, the Company and each of the Shareholders waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach. 

(j) Attorneys’ Fees. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

(k) Joint Product. This Agreement is the joint product of the Company and the other parties hereto and each
provision hereof and thereof has been subject to the mutual consultation, negotiation and agreement of the Company and the other parties hereto and shall not be construed against any party hereto. 

(l) Delays or Omissions. Except as expressly provided herein, no delay or omission to exercise any right,
power or remedy accruing to any party, upon any breach or default of another party under this Agreement, shall impair any such right, power or remedy of such party nor shall it be construed to be a waiver of any such breach or default, or an

  
 9 

 
acquiescence therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this
Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 (m) Interpretation. The words “include,” “includes” and
“including” when used herein shall be deemed in each case to be followed by the words “without limitation.” The titles and subtitles used in this Agreement are used for convenience only and are not considered in construing or
interpreting this Agreement. 
 (n) Telecopy Execution and Delivery. A facsimile, telecopy or other
reproduction of this Agreement may be executed by one or more parties to this Agreement, and an executed copy of this Agreement may be delivered by one or more parties to this Agreement by facsimile or similar electronic transmission device pursuant
to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party to this Agreement, all parties to this Agreement agree
to execute an original of this Agreement as well as any facsimile, telecopy or other reproduction of this Agreement. 
 (o) Sale, Sell, Transfer, etc. The words “sale,” “sell,” “transfer,” and the like shall include any disposition by way of transfer with or without
consideration, to any persons for any purpose and include, without limitation, public or private offerings, exchanges, mergers, consolidations, reorganizations, redemptions, or any other transaction affecting the stock of the Company held by the
Common Shareholders and Investors. 
 (p) Ownership. Each Common Shareholder and each Investor
represents and warrants that, as of the date hereof, such Common Shareholder or Investor is the sole and legal owner, beneficially and of record, of the shares of stock subject to this Agreement and that no other person has any right, title or
interest (other than a community property interest) in such shares. 
 (q) Stock Splits, Stock Dividends,
etc. In the event of any stock split, stock dividend, recapitalization, reorganization, or the like, any securities issued with respect to the shares of Common Stock or Preferred Stock held by the Common Shareholders or Investors shall
become subject to the terms of this Agreement. 
 (r) Aggregation of Stock. All
shares of the Company’s Stock held or acquired by a Shareholder and its Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. For purposes of the foregoing, any shares of
Stock held by a Shareholder that (X) is a partnership, limited liability company or corporation shall be deemed to include shares held by (i) entities affiliated with such partnership, limited liability company or corporation,
(ii) any partner (or retired partner), member (or retired member) or stockholder of such partnership, limited liability company or corporation, (iii) the 

  
 10 

 
spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or stockholder, (iv) the estate of any such partner (or retired
partner), member (or retired member) or stockholder and (v) any custodian or trustee for the benefit of any such partner (or retired partner), member (or retired member) or stockholder or the spouse, siblings, lineal descendants or ancestors of
any such partner (or retired partner), member (or retired member) or stockholder or (Y) is an individual shall be deemed to include shares held by (i) the estate of such individual or (ii) the spouse, siblings, lineal descendants or
ancestors of such individual and any custodian or trustee for the benefit of any of the foregoing persons. Notwithstanding the foregoing, in the event that the holders of a particular series of Preferred Stock are entitled to exercise a right
hereunder, the holders of that particular series of Preferred Stock who are a party to this Agreement shall not be permitted to aggregate any other shares of Stock other than shares of that particular series of Preferred Stock for the purposes of
determining the availability of such right under this Agreement. 
 [Signature Pages Follow] 

  
 11 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement to be effective as of the date first set forth above. 
  

			
	COMPANY:
	
	WHITEGLOVE HOUSE CALL HEALTH, INC.
		
	By:	 	/s/ Robert A. Fabbio
		 	Robert A. Fabbio
		 	President and Chief Executive Officer

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement to be effective as of the date first set forth above. 
  

			
	INVESTORS: 
	
	TRAFLT, LLC
		
	By:	 	/s/ Robert A. Fabbio
		 	Manager

 WHITEGLOVE
HOUSE CALL HEALTH, INC. 
 SIGNATURE
PAGE TO THIRD AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement to be effective as of the date first set forth above. 
  

			
	INVESTORS:
	
	 IRA FBO Robert A. Fabbio Pershing LLC as
 Custodian Account Number: 5U9 986364

		
	By:	 	/s/ Robert A. Fabbio
		 	Robert A. Fabbio

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO THIRD AMENDED AND
RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement as of the date first set forth above. 
  

	
	INVESTORS:
	
	/s/ William Rice
	William Rice

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO THIRD AMENDED AND
RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	HQ INVESTORS 3, LLC
		
	By:	 	/s/ Lawrence Garatoni
		 	Lawrence Garatoni, Authorized Member

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO THIRD AMENDED AND
RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	WR HAMBRECHT VENTURES II, L.P.
		
	By:	 	/s/ Alan Katz
	Name:	 	Alan Katz
	Title:	 	Manager

 WHITEGLOVE
HOUSE CALL HEALTH, INC. 
 SIGNATURE
PAGE TO THIRD AMENDED AND RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	HIDDEN LION PARTNERS I, LLC
		
	By:	 	Hidden Lion Partners Management Company, LLC, its Managing Director
		
	By:	 	/s/ Mark Sherman
		 	Mark Sherman, Managing Director

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO THIRD AMENDED AND
RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement as of the date first set forth above. 
  

			
	INVESTORS:
	
	ENHANCED EQUITY FUND II, L.P.
		
	By:	 	EEF Partners II LLC, its General Partner
		
	By:	 	/s/ Malcolm T. Kostuchenko
		 	Malcolm T. Kostuchenko, Managing Partner
	
	EEF II CO-INVEST LLC 
		
	By:	 	/s/ Andrew M. Paul
		 	Andrew M. Paul, Sole Member

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement to be effective as of the date first set forth above. 
  

	
	COMMON SHAREHOLDERS:
	
	/s/ Robert A. Fabbio
	Robert A. Fabbio

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO THIRD AMENDED AND
RESTATED VOTING AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Voting
Agreement to be effective as of the date first set forth above. 
  

	
	COMMON SHAREHOLDERS:
	
	  
	Robert A. Fabbio

WHITEGLOVE HOUSE CALL HEALTH, INC. 

SIGNATURE PAGE TO THIRD AMENDED AND
RESTATED VOTING AGREEMENT 

 SCHEDULE I 

SCHEDULE OF INVESTORS 

 

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 IRA FBO “Robert A. Fabbio”

c/o Pershing, LLC

One Pershing Plaza

Jersey City, NJ 07399
	  				  	 	68,302	  	  	 	113,837	  	  				  			
						
	 TRAFLT, LLC

215 Bella Riva
 Austin, Texas 78734
 Fax: 512-266-7330
	  	 	2,216,667	  	  	 	32,448	  	  				  				  			
						
	 Monica Fabbio

215 Bella Riva
 Austin, Texas 78734
 Fax: 512-266-7330
	  				  	 	40,000	  	  				  				  			
						
	 Wilson G. Allen

403 Buckeye Trail

Austin, Texas 78746

wilson@westlakellc.com
	  				  	 	50,000	  	  				  				  			
						
	 Rudge Allen Investment Company

403 Buckeye Trail

Austin, Texas 78746

wilson@westlakellc.com
	  				  	 	25,000	  	  				  				  			
						
	 Eric Rothfus

4 Coleridge Lane
 Austin, Texas 78746

eric.rothfus@guggenheimpartners.com
	  				  	 	50,000	  	  				  				  			
						
	 Ed Ateyeh

4410 Michaels Cove

Austin, Texas 78746

taylor@colltech.com
	  				  	 	50,000	  	  	 	22,767	  	  				  			
						
	 Laura J. Kilcrease

7504 Clove Cove
 Austin, Texas 78750
 Fax: 512-346-0082

laura@tritonventures.com
	  				  	 	25,000	  	  	 	11,383	  	  				  			
						
	 Famiglia Ciola, LLC

803 Hurst Creek Road

Austin, Texas 78734

dciola@asglp.com
	  				  	 	50,000	  	  				  	 	14,632	  	  			
						
	 Paul Twitchell

2011 Crosby Road
 Wayzata, Minnesota 55391

ptwitchell@whiteboxadvisors.com
	  				  	 	50,000	  	  	 	45,535	  	  				  			
						
	 Meredith Family Revocable Trust

248 Addie Roy Road, Suite C-200

Austin TX 78742
 Fax: 512-732-0225
	  				  	 	266,600	  	  	 	190,000	  	  	 	61,282	  	  			

 SCHEDULE I 

  

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 JMM PTLP Ltd.

c/o Randy McFadden

Telephone Management

609 Castle Ridge Road, Suite 215

Austin, Texas 78746

512-327-4454
 (fax) 512-327-5561
 rmcfadden@telephonemanagement.com

	  				  	 	125,000	  	  				  				  			
						
	 Nicholas J. Nascone

217 Bella Riva
 Austin, Texas 78734
 512-413-3657

nick@nascone.com
	  				  	 	25,000	  	  	 	11,384	  	  				  			
						
	 Jeffrey S. Muir

Fulcrum Ventures
 1040 Crown Pointe Parkway, Suite 330
 Atlanta, Georgia
30338
 770-551-6300

(fax) 770-551-6330
	  				  	 	12,500	  	  				  				  			
						
	 William Rice

3601 Travis County Circle

Austin, Texas 78735

brice@housecallhealth.com
	  	 	1,108,333	  	  	 	1,350	  	  				  				  			
						
	 Michael Hancock

3701 Whitt Loop
 Austin, Texas 78749
 512-422-3093

mhancock@housecallhealth.com
	  				  	 	2,652	  	  				  	 	776	  	  			
						
	 HQ Investors 3, LLC

Anthony Wright
 1150 Lakeway Drive, Suite 207
 Austin, TX 78734

tony.wright@hqinvestments.com
	  				  				  	 	684,655	  	  	 	199,166	  	  			
						
	 W. W. McAllister III

4940 Broadway #305

San Antonio, TX 78209

bomcallister@sbcglobal.net
	  				  				  	 	68,302	  	  				  			
						
	 Three Lee Investments Limited

970 Isom Road
 San Antonio, TX 78209
 Fax: 866-511-1249

slee@qlee.net
	  				  				  	 	136,604	  	  				  			
						
	 Andrews Kurth LLP

111 Congress Ave., Suite 1700

Austin, Texas 78701

Attn: Carmelo M. Gordian

Fax: 512-320-9292
	  				  				  	 	6,830	  	  				  			

 SCHEDULE I 

  

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 St. James’s Park Ventures, LP

3801 N. Capital of Texas Highway

Suite E-240, #62
 Austin, TX 78746
 steve@sjpholding.com
	  				  				  	 	45,535	  	  	 	61,282	  	  			
						
	 Will McAlister

4940 Broadway #305

San Antonio, TX 78209

Fax: 210-824-7028
	  				  				  	 	22,767	  	  				  			
						
	 WR Hambrecht Ventures II, L.P.

Margo Ranucci
 WR Hambrecht + Co
 Private Equity

Administrator/Compliance

Administrator
 Pier 1, Bay 3
 San Francisco, CA 94111

Tel. (415) 551-8649

Fax: (415) 551-8625

mranucci@wrhambrecht.com
	  				  				  	 	387,049	  	  				  			
						
	 Spersibs, LP

5300 Bee Cave Road

Bldg 1-220
 Austin, TX 78746
 Phil@psper.com
	  				  				  	 	20,400	  	  	 	13,727	  	  			
						
	 Accent Texas Fund II, L.P.

5300 Bee Caves Road

Building 1, Suite 240

Austin, TX 78746
 Attention: Mansoor Ghori
 Fax: 5120306-9967

mansoororg@accentcap.com
	  				  				  				  	 	76,603	  	  			
						
	 Hidden Lion Partners I, LLC

Attn: Mark Sherman

2506 Union Street

San Francisco, CA 94123

Tel. (415) 734-1977

Fax: (415) 996-3355

mark@hiddenlion.com
	  				  				  				  	 	1,532,050	  	  			
						
	 Enhanced Equity Fund II, L.P.

Attn: Malcolm T. Kostuchenko

c/o Enhanced Capital Partners, Inc.

601 Lexington Avenue, 55th Floor
 New York, NY 10022
 Fax: 212-207-3386
	  				  				  				  				  	 	2,182,858	  

 SCHEDULE I

  

																					
	 INVESTOR
	  	SERIES A
PREFERRED
STOCK
HELD	 	  	SERIES A-1
PREFERRED
STOCK
HELD	 	  	SERIES B-1
PREFERRED
STOCK
HELD	 	  	SERIES C
PREFERRED
STOCK
HELD	 	  	SERIES D
PREFERRED
STOCK
HELD	 
	 EEF II Co-Invest LLC

Attn: Malcolm T. Kostuchenko

c/o Enhanced Capital Partners, Inc.

601 Lexington Avenue, 55th Floor
 New York, NY 10022
 Fax: 212-207-3386
	  				  				  				  				  	 	133,619	  
						
	 Enhanced Capital Texas Fund II, LLC

Attn: Paul Kasper

c/o Enhanced Capital Partners, Inc.

601 Lexington Avenue, 55th Floor
 New York, NY 10022
 Fax: 212-207-3386
	  				  				  				  	 	153,205	  	  			
						
	 Andrew M. Paul

283 Pondfield Road

Bronxville, NY 10708

Fax: 212-207-3386

apaul@enhancedcap.com
	  				  				  				  	 	153,205	  	  			
						
	 Jonathon Kaiden

515 W. 52nd Street
 Apartment PHIF
 New York, NY 10019

Fax: 212-207-3386

jkaiden@enhancedcap.com
	  				  				  				  	 	7,660	  	  			
						
	 Barry Osherow

32 South Bedford Rd.

Pound Ridge, NY 10576

bosherow@yahoo.com
	  				  				  				  	 	3,064	  	  			
						
	 Paul S. Kasper

161 Hudson Street

Apt #2C
 New York, NY 10013
	  				  				  				  	 	7,660	  	  			
						
	 Michael Korengold

10 Dellwood Circle

Bronxville, NY 10708

Fax: 212-207-3386

mkorengold@enhancedcap.com
	  				  				  				  	 	4,596	  	  			
		  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 TOTAL
	  	 	3,325,000	  	  	 	873,852	  	  	 	1,767,048	  	  	 	2,288,908	  	  	 	2,316,477	  
		  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 

 SCHEDULE I 

  

 SCHEDULE II 

SCHEDULE OF COMMON SHAREHOLDERS 

 

					
	 Name/Address
	  	Common Shares	 
	 Robert A. Fabbio
 215 Bella Riva
 Austin, Texas 78734
 Fax: 512-266-7330
 Email: bob@fabbio.com
	  	 	33,814	  
		
	 William Rice
 3601 Travis County Circle
 Austin, Texas 78735

brice@housecallhealth.com
	  	 	16,186	  
		
	 Danny Bone
 130 Walnut Tree Loop
 Georgetown TX 78633
	  	 	12,000	  
		
	 Sebastian Brocher
 7313 Rimcrest Cove
 Austin TX 78735
	  	 	43,496	  
		
	 George Catlin
 5304 Wishek Cove
 Austin TX 78730
	  	 	6,000	  
		
	 Richard Willis
 2701 Regents Park
 Austin TX 78746
	  	 	30,500	  
		
	 Kylie Jordan Bruehler Irrevocable Trust
	  	 	5,000	  
		
	 Majin Castillo
 1300 Annie Lane
 Libertyville, IL 60048
	  	 	7,500	  
		
	 Donnie Hromadka
 3104 Fort Worth Trail
 Austin TX 78748
	  	 	10,000	  
		
	 Jimmy Treybig
 10915 Bee Caves Road
 Austin TX 78733
	  	 	39,000	  
		  	 	 	 
	 Total
	  	 	203,496	  
		  	 	 	 

  

SCHEDULE II 

 EXHIBIT A  

FORM OF INDEMNITY AGREEMENT 

  

EXHIBIT A 

 EXHIBIT B 

ADOPTION AGREEMENT 
 This Adoption Agreement (“Adoption Agreement”) is executed by the undersigned (the “Transferee”) pursuant to the terms of that certain Third Amended and
Restated Voting Agreement dated as of March 2, 2011, (the “Agreement”) by and among Whiteglove House Call Health, Inc., a Texas corporation (the “Company”), and certain of its Shareholders.
Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Adoption Agreement, the Transferee agrees as follows: 

1. Acknowledgement. Transferee acknowledges that Transferee is acquiring certain shares of the capital stock of the Company
(the “Stock”), which shares are subject to the terms and conditions of the Agreement. 
 2.
Agreement. As partial consideration for such transfer, Transferee (i) agrees that the Stock acquired by Transferee shall be bound by and subject to the terms of the Agreement, to the same extent and with the same rights and
obligations as the person(s) from which such Stock is received and (ii) hereby agrees to become a party to the Agreement with the same force and effect as if Transferee were originally a party thereto. 

3. Notice. Any notice required or permitted by the Agreement shall be given to Transferee at the address
listed below Transferee’s signature below. 
 4. Joinder. The spouse of the undersigned Transferee, if
applicable, executes this Adoption to acknowledge its fairness and that it is in such spouse’s best interests and to bind to the terms of the Agreement such spouse’s community interest, if any, in the Stock. 

EXECUTED AND DATED this          day of
                    ,          . 

 

			
	TRANSFEREE:
	
	 
	Title:	 	 
	Address:	 	 
	Fax:	 	 
	
	Spouse: (if applicable):
	
	 
	Name:	 	 

 Acknowledged and accepted on
                    ,           

 

			
	WHITEGLOVE HOUSE CALL HEALTH, INC.
		
	By:	 	 
	Name:	 	 
	Title:	 	 

  

EXHIBIT B 

 EXHIBIT C 

SIGNATURE PAGE TO WHITEGLOVE HOUSE CALL HEALTH, INC. 
 THIRD AMENDED AND RESTATED VOTING AGREEMENT 
 The undersigned hereby
executes, delivers and agrees to become a party as a Common Shareholder under the Third Amended and Restated Voting Agreement dated March 2, 2011 (the “Agreement”). Schedule II to the Agreement is hereby
amended to add the Common Shareholder as set forth below. 
 EXECUTED AND DATED this
         day of                     
,          . 
  

											
	[signature block for entities]	 		 	 
		 		 		 	(Print Name of Entity)
					
		 		 		 	By:	 	 
					
		 		 		 	Name:	 	 
					
		 		 		 	Title:	 	 
			
	[signature block for entities]	 		 	 
		 		 		 	(Signature)
			
		 		 	 
		 		 		 	(Print Name of Individual)
					
		 		 		 	Address:	 	 
				
		 		 		 	 
					
		 		 		 	Fax:	 	 

 Acknowledged and accepted on
                    ,           

 

			
	WHITEGLOVE HOUSE CALL HEALTH, INC.
		
	By:	 	 
	Name:	 	Robert A. Fabbio
	Title:	 	Chief Executive Officer

  

EXHIBIT C

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}]]